Please login to the form below
aclidinium
This page shows the latest aclidinium news and features for those working in and with pharma, biotech and healthcare.
Circassia seeks shift to AIM after failing LSE criteria
The Oxford-based company is buying US commercial rights to AstraZeneca’s chronic obstructive pulmonary disease (COPD) medicine Tudorza (aclidinium bromide), a drug that the two companies have partnered since 2017. ... Duaklir (aclidinium/formoterol)
Latest news
-
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
-
GSK's triple COPD therapy tops Symbicort in phase III trial
These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
-
GSK brings forward triple COPD therapy filing in US
GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
-
Boehringer bags FDA approval for Spiriva-based combo
AstraZeneca is also bringing its aclidinium bromide/formoterol fumarate product -sold in Europe as Duaklir - through the latter stages of development.
-
GSK sees COPD future in triple therapy
Duaklir (formoterol fumarate and aclidinium bromide) jostling for market share.
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Interview: Jorge Gallardo, Almirall
We now have five R&D projects about to start or already in phase III and we are intending to register another two projects in 2011: aclidinium bromide for chronic obstructive
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Client Services Director- Flexible Working
-
Negotiable
- Account Manager – Healthcare advertising
-
Salary TBC
-
Events Executive
-
DOE
-
Account Director – UK Office
-
Excellent salary and benefits
-
Senior Medical Writer
-
Competitive salary plus benefits
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- AbbVie/Allergan's merger faces public opposition
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Report: Customer experience, shaping digital healthcare
- The benefits of uniting in a divergent environment
- Encouraging signs in biomarker R&D
- J&J puts pressure on rivals with new Erleada okay in prostate cancer
- Pharma exhibition stand design with added value
- Bluebird Bio reveals further encouraging data for CALD gene therapy
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
